drugset
drugset / Trial / NCT05036512

A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants

NCT05036512 ↗

Phase 1 Completed 129 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This first in human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and food effect of GBT021601, a hemoglobin S (HbS) polymerization inhibitor, in healthy participants.

Timeline

Start
2020-12-09
Primary completion
2022-11-02
Completion
2023-02-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Osivelotor Small molecule — Oral

Indications

sickle cell disease